This article first appeared on GuruFocus .
Release Date: May 08, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
YDUQS Participacoes SA ( BSP:YDUQ3 ) reported a strong cash generation of 276 million in the first quarter, marking a record for the company.
-
The company has successfully reduced its Days Sales Outstanding (DSO), leading to improved cash flow and reduced bad debt.
-
EBEMEC and EDOMED brands showed significant growth, with EBEMEC achieving a 23% revenue increase year over year.
-
The company is maintaining a stable margin despite challenging macroeconomic conditions, indicating strong operational efficiency.
-
YDUQS Participacoes SA ( BSP:YDUQ3 ) continues to invest in AI initiatives to enhance productivity and efficiency across its operations.
Negative Points
-
The company faces challenges in the demand for B&C class products due to income constraints and community indebtedness.
-
There is increased competition in the medical education sector, impacting intake and market dynamics.
-
The new regulatory framework for distance learning has created uncertainties and challenges in student enrollment.
-
YDUQS Participacoes SA ( BSP:YDUQ3 ) is experiencing a drop in revenue due to adjustments in revenue recognition and accounting practices.
-
The macroeconomic environment, including high family indebtedness and election year uncertainties, poses challenges for growth and stability.
Q & A Highlights
-
Warning! GuruFocus has detected 4 Warning Sign with BSP:YDUQ3.
-
Is BSP:YDUQ3 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you elaborate on the sustainability of the reduction in Days Sales Outstanding (DSO) and the factors contributing to this improvement? A: (CEO, Rossano Marques) The reduction in DSO is sustainable and part of a strategic move to clean up results, making them more stable and predictable. This involves reducing bad debt and improving the provision for non-engaged students. We have room for further improvement, and these actions are planned and structured to align with our market strategy. (CFO, Alexandre Aquino) We have seen a temporary improvement due to changes in the Pravalir program, and we expect further reductions in accounts receivable, which will stabilize at lower levels.
Q: What is the outlook for the margin stability in the guidance, and how does it break down across different business units? A: (CFO, Alexandre Aquino) We expect the margin to remain stable year over year. The decline in the TIS has impacted margins, but if excluded, we would see a 1% point increase. Looking ahead, we anticipate stability in the second half, with premium brands like EDOMED and EBEMEC maintaining or improving their margins.
Q: How does the company plan to address the challenges posed by the new regulatory framework and its impact on the sustainability of partner centers? A: (Rodolfo, Vice President of Operations) We are focused on ensuring the profitability and sustainability of partner centers by providing business consultants and data to help partners understand their profitability. The new legal framework requires adjustments, but we are confident in maintaining the sustainability of our centers through diversified revenue streams and strategic adaptations.
Q: Can you provide more details on the competitive landscape in medical education and how it affects your strategy? A: (CEO, Rossano Marques) The medical education market is experiencing increased competition due to new seat offerings. However, our EDOMED brand has achieved a record intake of 2,000 students, demonstrating its strong positioning. We focus on maintaining high-quality standards and leveraging our established presence in key markets to navigate this competitive environment.
Q: What is the company's approach to capital allocation, and is there a plan to establish a specific dividend policy? A: (CEO, Rossano Marques) Our primary focus is on reducing leverage to achieve a net debt to EBITDA ratio of one by 2027. We will continue to be opportunistic with buybacks and M&A, as seen with our recent acquisition of Unifamentro. Dividend payments will remain stable, following our framework, until we reach our leverage goal, after which we may establish a more defined dividend policy.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
